查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1714339

胃癌治疗市场－全球产业规模、份额、趋势、机会及预测，依治疗类型、最终用户、地区及竞争情况细分，2020-2030 年预测

Gastric Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapy Type, By End User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球胃癌治疗市场价值为 39.8 亿美元，预计到 2030 年将达到 57 亿美元，复合年增长率为 6.12%。胃癌是一种起源于胃黏膜的恶性肿瘤，需要多方面的治疗方法，包括手术、化疗、放射疗法、标靶疗法、免疫疗法和联合治疗。市场成长主要受到全球胃癌发病率上升的推动，特别是在东亚和拉丁美洲等地区，以及诊断技术和治疗创新的进步。提高认识和早期检测措施有助于获得更好的临床结果。精准医疗和基于生物标记的疗法的发展也在重塑治疗格局。儘管取得了这些进步，但市场仍面临着治疗成本高、治疗抵抗力强以及某些地区获得尖端医疗服务的机会有限等挑战。儘管如此，持续的研究、製药公司之间的合作以及以患者为中心的护理策略正在推动市场走向更个人化和有效的治疗解决方案。

市场概览
预测期 2026-2030
2024年市场规模 39.8亿美元
2030年市场规模 57亿美元
2025-2030 年复合年增长率 6.12%
成长最快的领域 标靶治疗
最大的市场 北美洲

关键市场驱动因素

胃癌发生率上升

主要市场挑战

晚期治疗选择有限

主要市场趋势

免疫疗法占主导地位

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：胃癌治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依治疗类型（化疗、标靶治疗、免疫治疗、放射治疗、手术）
    • 按最终使用者（门诊手术中心、医院和专科诊所、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美胃癌治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲胃癌治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第八章：亚太胃癌治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：南美胃癌治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲胃癌治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 13 章： 大环境分析

第 14 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章：全球胃癌治疗市场：SWOT 分析

第 16 章：竞争格局

  • Abbott Laboratories Inc.
  • Amgen, Inc.
  • Celltrion Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies Inc.
  • AstraZeneca Plc
  • Pfizer Inc.
  • Eli Lilly & Co.
  • GlaxoSmithKline Plc.

第 17 章：策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 16096

The Global Gastric Cancer Therapy Market was valued at USD 3.98 billion in 2024 and is projected to reach USD 5.70 billion by 2030, growing at a CAGR of 6.12%. Gastric cancer, a malignancy originating in the stomach lining, requires a multifaceted approach to treatment that includes surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and combination treatments. Market growth is primarily fueled by the rising global incidence of gastric cancer, particularly in regions such as East Asia and Latin America, as well as advancements in diagnostic techniques and therapeutic innovations. Increasing awareness and early detection initiatives have contributed to better clinical outcomes. Precision medicine and the development of biomarker-based therapies are also reshaping the treatment landscape. Despite these advancements, the market faces challenges such as high treatment costs, resistance to therapy, and limited access to cutting-edge care in certain regions. Nonetheless, continuous research, partnerships among pharmaceutical players, and patient-centered care strategies are propelling the market toward more personalized and effective therapeutic solutions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.98 Billion
Market Size 2030USD 5.70 Billion
CAGR 2025-20306.12%
Fastest Growing SegmentTargeted Therapy
Largest MarketNorth America

Key Market Drivers

Rising Incidence of Gastric Cancer

The increasing incidence of gastric cancer is a critical driver of the Global Gastric Cancer Therapy Market. In 2020, over 1.1 million new gastric cancer cases were reported globally, with approximately 770,000 related deaths. The disease is notably more prevalent in males, and Eastern Asia continues to report the highest incidence. Aging populations, lifestyle factors such as smoking and dietary habits, and environmental exposures contribute to the disease's global rise. Regions like Japan, China, South Korea, and parts of Latin America and Europe exhibit particularly high prevalence. In India, for example, northeastern districts like Aizawl and Papumpare have recorded alarmingly high age-adjusted rates. As early detection improves and more cases are diagnosed, the demand for effective treatment options has intensified. This trend is driving the expansion of chemotherapy, immunotherapy, and targeted therapy offerings to meet the growing therapeutic needs of patients worldwide.

Key Market Challenges

Limited Treatment Options for Advanced Stages

Advanced-stage gastric cancer presents a major treatment challenge, largely due to its aggressive progression and resistance to conventional therapies. Once the cancer has metastasized, standard treatments such as chemotherapy, targeted therapies, and immunotherapy may lose efficacy due to genetic mutations and immune evasion mechanisms developed by cancer cells. As a result, treatment outcomes in advanced stages remain limited. Research is increasingly focusing on combination therapies and novel targets to overcome resistance and improve survival rates. Clinical trials are critical in evaluating these innovations and expanding the therapeutic arsenal. However, access to these new treatments is often limited by geographic, economic, and regulatory constraints. Overcoming these hurdles will require coordinated efforts among research institutions, pharmaceutical companies, and regulatory bodies to broaden treatment options and ensure equitable access for patients battling advanced gastric cancer.

Key Market Trends

Immunotherapies Dominance

Immunotherapy is emerging as a dominant force in the Global Gastric Cancer Therapy Market, revolutionizing the traditional treatment approach by leveraging the immune system to fight cancer. Immune checkpoint inhibitors-such as those targeting PD-1, PD-L1, and CTLA-4-have demonstrated remarkable success in treating patients with advanced gastric cancer. These therapies have led to longer survival and improved quality of life for some patients who previously had limited treatment options. Their ability to generate durable immune responses has opened up new possibilities, especially when used in combination with chemotherapy or targeted therapy. However, response rates vary, and immune-related adverse events remain a concern. Ongoing research is focused on identifying biomarkers to better predict patient response, optimizing treatment combinations, and reducing side effects. As clinical evidence grows and regulatory approvals expand, immunotherapies are expected to remain central to the evolving landscape of gastric cancer treatment, driving innovation and offering renewed hope for improved patient outcomes.

Key Market Players

  • Abbott Laboratories Inc.
  • Amgen, Inc.
  • Celltrion Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies Inc.
  • AstraZeneca Plc
  • Pfizer Inc.
  • Eli Lilly & Co.
  • GlaxoSmithKline Plc.

Report Scope:

In this report, the Global Gastric Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gastric Cancer Therapy Market, By Therapy Type:

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Radiation Therapy
  • Surgery

Gastric Cancer Therapy Market, By End User:

  • Ambulatory Surgery Centers
  • Hospitals and Specialty Clinics
  • Other

Gastric Cancer Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastric Cancer Therapy Market.

Available Customizations:

Global Gastric Cancer Therapy Market report with the given Market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Gastric Cancer Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery)
    • 5.2.2. By End User (Ambulatory Surgery Centers, Hospitals and Specialty Clinics, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Gastric Cancer Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gastric Cancer Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Gastric Cancer Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Gastric Cancer Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy Type
        • 6.3.3.2.2. By End User

7. Europe Gastric Cancer Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gastric Cancer Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy Type
        • 7.3.1.2.2. By End User
    • 7.3.2. United Kingdom Gastric Cancer Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy Type
        • 7.3.2.2.2. By End User
    • 7.3.3. Italy Gastric Cancer Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy Type
        • 7.3.3.2.2. By End User
    • 7.3.4. France Gastric Cancer Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Gastric Cancer Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy Type
        • 7.3.5.2.2. By End User

8. Asia-Pacific Gastric Cancer Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Gastric Cancer Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Gastric Cancer Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Gastric Cancer Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Gastric Cancer Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Gastric Cancer Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy Type
        • 8.3.5.2.2. By End User

9. South America Gastric Cancer Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Gastric Cancer Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy Type
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Gastric Cancer Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy Type
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Gastric Cancer Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy Type
        • 9.3.3.2.2. By End User

10. Middle East and Africa Gastric Cancer Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Gastric Cancer Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Gastric Cancer Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy Type
        • 10.3.2.2.2. By End User
    • 10.3.3. UAE Gastric Cancer Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Global Gastric Cancer Therapy Market: SWOT Analysis

16. Competitive Landscape

  • 16.1. Abbott Laboratories Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Product & Service Offerings
    • 16.1.3. Recent Developments
    • 16.1.4. Financials (If Listed)
    • 16.1.5. Key Personnel
    • 16.1.6. SWOT Analysis
  • 16.2. Amgen, Inc.
  • 16.3. Celltrion Inc.
  • 16.4. Novartis AG
  • 16.5. F. Hoffmann-La Roche Ltd
  • 16.6. Agilent Technologies Inc.
  • 16.7. AstraZeneca Plc
  • 16.8. Pfizer Inc.
  • 16.9. Eli Lilly & Co.
  • 16.10.GlaxoSmithKline Plc.

17. Strategic Recommendations

18. About Us & Disclaimer